Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region-Reference-Cited by-同舟云学术

Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region

Published:2022-11 Issue:6 Volume:36 Page:781-789
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Alpalhão Miguel^ORCID,Duarte Joana,Diogo Rita,Vandemeulebroecke Marc,Ortmann Christine-Elke,Kasparek Torben,Filipe Paulo

Funder

Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-022-00558-2.pdf

Reference28 articles.

1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71.

2. Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat. 2018;29:220–9.

3. Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of secukinumab on moderate to severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6:639–47.

4. Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8:571–9.

5. Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–17.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study;Clinical, Cosmetic and Investigational Dermatology;2024-06

2. The clinical spectrum of response to narrowband‐UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult‐to‐treat body region;Photodermatology, Photoimmunology & Photomedicine;2023-05

3. Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry;Dermatology and Therapy;2022-12-23